Skip to main content
TipRanks
Go Ultimate75% OFF

Orasure Technologies (OSUR) AI Stock Analysis

648 Followers
OSUR

Orasure Technologies

(NASDAQ:OSUR)

Select Model
Rating:45Neutral
Price Target:$3.50â–²(1.16% Upside)
Action:reiterated
Date:11/10/26

The overall score is 45, reflecting a high-risk profile. The primary drag is the company's poor financial performance, marked by significant losses and cash burn, which overshadows a strong balance sheet. While the latest earnings call indicates a potential turnaround with a return to growth, this positive signal is not yet reflected in the financial statements or technical trends, which remain weak. The delayed path to cash flow breakeven is a critical risk factor.

Positive Factors
Debt-free balance sheetA debt-free balance sheet with substantial cash gives OraSure financial resilience while it funds product development and commercial expansion. Low leverage reduces refinancing pressure and preserves flexibility to absorb ongoing losses, pursue partnerships, and support growth initiatives over the next several quarters.
Negative Factors
Persistent operating losses and cash burnContinued operating losses alongside negative operating cash flow show that current revenue is not yet supporting the cost structure. Persistent cash burn can consume financial resources, delay self-funding growth, and require further expense reductions before profitability becomes durable.

Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%OSUR+41.22%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$249.26M
Dividend Yield
―
Average Volume (3M)
575.72K
Price to Earnings (P/E)
-5.2
Beta (1Y)
0.85
Revenue Growth
-7.53%
EPS Growth
14.93%
Country
US
Employees
500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Orasure Technologies Business Overview & Revenue Model

Company Description

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, E...

How the Company Makes Money

OraSure makes money primarily by selling diagnostic tests and sample collection/collection-device products to customers such as public health agencies, hospitals and clinics, laboratories, distributors, and other healthcare-related organizations. A k...

Orasure Technologies Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-1.98%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was broadly positive, reflecting a return to growth, strong performance in Diagnostic Products and Sample Management Solutions, gross margin expansion, lower operating spend, a debt-free balance sheet, and confidence in 2027 revenue acceleration. However, the company remains loss-making with negative operating cash flow, delayed cash flow breakeven, uncertain CT/NG regulatory timing, and delayed Ebola contracting catalysts. The highlights significantly outweighed the lowlights.

Positive Updates

Return to Revenue Growth
OraSure delivered 2026 third-quarter revenue of $30.9 million, up 14% year over year and approximately 1% sequentially. Management characterized the quarter as another solid quarter of execution and a return to growth.

Negative Updates

Operating Losses Persist
GAAP operating income in Q3 was a loss of $13.0 million, while non-GAAP operating loss was $10.2 million.

Company Guidance

For the fourth quarter, OraSure expects revenue between $30 million and $32 million, representing year-over-year growth of approximately 12% to 20%, with gross margin in Q4 expected to be similar to or slightly below Q3 and OpEx expected to be similar to Q3 overall; full year 2026 revenue is expected between $119.5 million and $121.5 million, implying a full year growth rate between 3.8% and 5.6%, with 4.7% at the midpoint. The company now expects to reach cash flow from operations breakeven in the second half of 2027 and expects full year revenue growth to accelerate in 2027 compared with 2026, with additional insights to be provided on the fourth quarter earnings call; it also expects strong growth on a year-over-year basis in Q4 and expects that Ebola and Colli-Pee will be part of the acceleration of growth referred to for 2027.

Orasure Technologies Financial Statement Overview

Summary

Financial performance is deeply challenged. The income statement shows a dramatic revenue collapse and significant net losses, while cash flow is severely negative, indicating ongoing cash burn. The only mitigating factor is a strong, debt-free balance sheet, but the overall financial health is poor due to unprofitable operations.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue116.23M115.02M185.83M405.47M387.48M233.67M
Gross Profit48.71M48.20M76.23M179.42M148.44M117.60M
EBITDA-40.21M-56.74M-6.83M77.20M-139.00K2.37M
Net Income-48.51M-68.73M-19.50M53.66M-17.13M-23.00M
Balance Sheet
Total Assets349.47M403.17M479.66M482.85M444.18M460.99M
Cash, Cash Equivalents and Short-Term Investments148.24M199.28M267.76M290.41M110.85M153.04M
Total Debt11.65M13.20M14.60M13.50M12.55M12.27M
Total Liabilities42.33M62.34M69.32M52.17M79.75M80.46M
Stockholders Equity307.13M340.83M410.34M430.67M364.43M380.53M
Cash Flow
Free Cash Flow-49.62M-53.22M23.58M131.28M-111.11M-83.50M
Operating Cash Flow-43.68M-49.02M27.37M141.58M-47.20M-35.38M
Investing Cash Flow-9.42M-6.81M-39.03M66.15M21.09M-5.50M
Financing Cash Flow-13.68M-16.94M-4.18M-3.02M-3.83M-2.82M

Orasure Technologies Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.46

Price Trends

50DMA3.74Negative
100DMA3.82Negative
200DMA3.57Positive

Market Momentum

MACD-0.07Negative
RSI47.94Neutral
STOCH68.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Neutral. The current price of 3.46 is below the 20-day moving average (MA) of 3.70, below the 50-day MA of 3.74, and below the 200-day MA of 3.57, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 68.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSUR.

Orasure Technologies Risk Analysis

Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our Business Could be Negatively Affected as a Result of Actions of Activist Stockholders.Q4, 2025
2.Share Repurchases Could Increase the Volatility of the Trading Price of Our Common Stock and Diminish Our Cash Reserves, and We Cannot Guarantee That Our Stock Repurchase Program Will Enhance Long-Term Stockholder Value.Q4, 2025
3.Disruptions at the FDA and Other Government Agencies, Including Staffing Constraints, and Funding Uncertainty, Could Delay or Prevent the Development, Review, Approval, or Commercialization of Our Products and Adversely Affect Our Business.Q4, 2025

Orasure Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

OSUR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UTMDUTMD73Outperform$202.20M21.238.78%1.75%-9.62%-5.65%
INFUINFU70Outperform$281.67M29.8915.77%―2.40%76.01%
SMTISMTI52Neutral$300.00M-91.44-42.22%―9.82%91.93%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
STXSSTXS47Neutral$101.86M-4.15-115.83%―4.83%15.55%
OSUROSUR45Neutral$249.26M-5.23-15.17%―-7.53%14.93%

* Healthcare Sector Average

Performance Comparison

-50%0%50%OSURINFUSTXSUTMDMBOTSMTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
OSUR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
OSUROrasure3.461.0442.98%
INFUInfuSystem Holdings, Inc.14.354.8450.89%
STXSStereotaxis0.94-1.42-60.08%
UTMDUtah Medical Products69.4915.3128.26%
MBOTMicrobot Medical0.68-1.24-64.58%
SMTISanara MedTech32.5512.8565.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026